NEW YORK--(BUSINESS WIRE)---- $AXL #AXL--Axelar Foundation today disclosed new strategic investments into the AXL token. The total of investments exceeded $30M. A number of crypto investment funds participated, including Arrington Capital, Distributed Global, Electric Capital, Laser Digital, C^2 Ventures, Plassa Capital, Wagmi Ventures, among others. "We've had the privilege of knowing the exceptional team behind Axelar for many years and have great admiration for their bold vision to become the 'internet of.
NEW YORK--(BUSINESS WIRE)---- $AXL #axelar--Axelar Foundation today announces it has appointed Brian Brooks, a leader in advancing regulatory clarity and institutional adoption of blockchain technology, to its newly formed Institutional Advisory Board. Axelar Foundation is the nonprofit organization established to support growth and adoption of Axelar Network, a decentralized blockchain interoperability platform. "Digitization and tokenization of financial assets such as stablecoins and real-world assets is cri.
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "AXL Inhibitors - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 16+ companies and 20+ pipeline drugs in AXL Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights Companies and academics are working to assess challenges and seek opportunities that could influence AXL Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve AXL Inhibitors. AXL Inhibitors Emerging Drugs Chapters This segment of the AXL Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Emerging Drugs
Examine American Axle's (AXL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
AXL's revenues and cash flows are likely to get hit by expected declines in North American light vehicle production and massive capital expenditure.
AXL's fourth-quarter 2024 results reflect a narrower loss and strong cash flow despite falling revenues across segments.
American Axle & Manufacturing Holdings, Inc. (NYSE:AXL ) Q4 2024 Earnings Conference Call February 14, 2025 10:00 AM ET Company Participants David Lim - Head, Investor Relations David Dauch - Chairman & Chief Executive Officer Chris May - Executive Vice President & Chief Financial Officer Conference Call Participants John Murphy - Bank of America Edison Yu - Deutsche Bank Doug Carson - Bank of America Operator Good morning. My name is Rocco, and I will be your conference facilitator today.
American Axle & Manufacturing (AXL) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.09 per share a year ago.
American Axle (AXL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) has updated on its latest vertical wells at the Alberta Llanos field in Colombia, and told investors that production rates for January exceeded forecasts – with net output rising above 4,500 barrels per day. In addition to the vertical wells, which are the subject of today operations update, the company is also planning to drill more horizontal wells after those drilled in 2024 proved successful.